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DETERMINING THE KNOWLEDGE AND PRACTICES OF  
OBSTETRICS HEALTHCARE PROFESSIONALS REGARDING  
MATERNAL INTRAPARTUM PERTUSSIS VACCINATION ADMINISTRATION 
 
 
An Abstract of the Scholarly Project by 
Kristie Mattix, BSN, RN 
 
 
Pertussis is a contagious respiratory disease that can occur in all age groups. Signs 
and symptoms of pertussis, however, are worse in infants and young children; likewise, 
the rates of severe cases, hospitalizations, and deaths are higher in this group as well. 
Vaccination against pertussis is the most effective way to combat this illness. In the last 
15 years, there have been a number of changes in the recommendations regarding 
vaccination against pertussis. In order for these recommendations to be followed, 
healthcare professionals must be aware of the guidelines as well as be knowledgeable 
about the condition they are trying to prevent.   
This study evaluated the knowledge and practice of obstetrics healthcare 
professionals in Bartlesville, Oklahoma, regarding maternal pertussis vaccination 
strategies and timing. It assessed their perceived knowledge and practice before an 
educational in-service regarding pertussis prevention strategies specifically related to 
pertussis vaccination and pregnancy. Immediately following the educational in-service, 
healthcare professionals were asked to report whether they had an increase in knowledge 
regarding pertussis and vaccination strategies and whether they plan to change their 
practice in the future as a result of information received. The participants of this study 
reported having an increase in knowledge regarding pertussis and vaccination strategies, 
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Throughout history a major cause of infant morbidity and mortality has been 
pertussis, also known as “whooping cough.” After the introduction of the pertussis 
vaccine in the 1940’s, the number of cases declined significantly. Unfortunately, pertussis 
once again threatens young infants despite vaccination efforts and availability (Forsyth et 
al., 2015).  
Pertussis is a highly contagious acute respiratory illness caused by Bordetella 
pertussis, which is transmitted by aerosolized droplets (Cornia & Lipsky, 2017). 
Vaccination is the primary method for preventing pertussis. Despite the availability of 
vaccination, increased incidence of pertussis continues even in populations with rate of 
high vaccine coverage. The primary source of pertussis in infants is direct family 
members, with parents contributing in 50-55% of reported cases (Wiley et al., 2013). 
Grandparents and adolescent siblings accounted for 8% and 20% transmission rates, 
respectively (Terranella et al., 2013).   
In adults and adolescents, clinical manifestations of pertussis are often less severe 
than in infants and children. If a person has received immunization previously, a 




production, sweating episodes, and sore throat. Complications of pertussis can result in 
pneumonia or otitis media (Cornia & Lipsky, 2017).  
Description of the Clinical Problem 
Bordetella pertussis can lead to serious manifestations in young infants, who are 
more susceptible (Walther et al., 2015). Clinical signs include respiratory distress such as 
rapid breathing, grunting, nasal flaring, and retractions. Other manifestations can include 
pneumonia, inability to feed, cyanosis, apnea with or without coughing, and seizures. 
Decreases in fluid or nutrition intake combined with possible vomiting while coughing 
can lead to ceasing or declining weight gain, resulting in a failure to thrive diagnosis 
(Yeh, 2017). 
Pertussis Vaccination 
In the early 1900s, a vaccine was developed using killed whole cell pertussis 
(wP). Later in the 1970s and 1980s, acellular pertussis (aP) vaccines were developed. The 
acellular pertussis vaccines had a lower rate of adverse reactions and were shown to also 
be effective against pertussis. This is the vaccine of choice today because of the lower 
incidence of side effects, but the whole cell vaccine may offer a higher level of immunity. 
The aP component is combined with the combination tetanus and diphtheria (Td) 
components to create the DTaP for children up to six years of age and Tdap vaccine for 
those over the age of seven (Chiappini, et al., 2013). 
Infants are not initially immunized against pertussis until two months of age and 
depend upon others to not expose them to the illness. Primary immunization is comprised 
of five doses of the DTaP vaccine. In their first year, infants receive doses of the pertussis 




administered at 18 months of age, and fifth dose around 4-6 years of age. Immunizations 
are specifically timed in order to gradually establish stronger immunity to the pertussis 
antigen. Between the first and fifth doses, the infant builds antibodies and generally has 
partial immunity. Young children remain vulnerable before the initial vaccine, but the 
risk of infection is decreased. After the first dose of DTaP, the vaccine effectiveness is 
only 55.3%, this increases to approximately 80% after the second dose (Quinn et al., 
2014). With this in mind, it is possible to further protect infants and young children with 
incomplete immunity by having high levels of herd immunity in another group.  
Herd Immunity 
Herd immunity, also known as community immunity or herd protection, may 
develop naturally in society as a result of large-scale exposure to and recovery from 
disease; it may be stimulated artificially by widespread vaccination programs. Immunity 
is actively or passively acquired. Active immunity is the most common contributor to 
herd immunity. In active immunity, the individual develops resistance to a disease as a 
result of antibody production in relation to the exposure to and recovery from an antigen 
or after immunization (Merrill, 2013). Immunity limits or stops the ability of an 
individual to acquire and or pass along a specific disease (McCance & Huether, 2014). 
The easiest and safest way to increase levels of immunity results from vaccination (Fine 
et al., 2011). An individual’s immune system cannot distinguish between a vaccination or 
natural infection, so it creates antibodies and an immune reaction in response to both; 
however, vaccines usually have fewer side effects and complications associated with 




Infants and young children can be partially protected from pertussis with high 
levels of immunity in adolescents and young adults. With this concept in mind, in 2005 
the Advisory Committee on Immunization Practices (ACIP) introduced the concept of 
“cocooning,” a form of herd immunity (as cited in Terranella et al., 2013). With herd 
immunity, an individual is thought to be protected from a disease if those around him are 
vaccinated against that disease. This decreases the likelihood of the individual coming 
into contact with an infected person. Family members who have not received a Tdap 
booster, including fathers and adolescent siblings, are encouraged to receive a booster 
vaccination of Tdap before the birth of an infant if not previously vaccinated. This allows 
the ability to shield or “cocoon” the infant with immunity. As a part of the cocooning 
strategy, mothers were also instructed to receive the vaccine in the immediate postpartum 
period, referred to as postpartum vaccination.  
Issue Significance 
Despite the initiatives created in 2005, pertussis cases and rates continued 
significantly in the infant population. Between 2001 and 2010 there were 27,995 reported 
cases of pertussis in infants less than one year of age in the United States. In this group 
there were a resulting 189 deaths. The majority of these deaths occurred among those less 
than 3 months old (Centers for Disease Control, 2017). In infants less than two months 
old, pertussis cases accounted for 57% of hospitalizations and 85% of deaths (Terranella 
et al., 2013).  
While pertussis can be prevented by immunization, lifelong protection, however, 
cannot be achieved by initial immunization or natural disease (Walther et al., 2015). 




or vaccination; for this reason, regular booster doses are needed (Chiappini et al., 2013). 
Due to decreasing immunity, adolescents should receive a Tdap booster immunization at 
11 to 18 years of age (Cornia & Lipsky, 2017). The ACIP recommends that adolescents, 
adults, and those over the age of 65 receive a dose of Tdap, especially if they are in close 
contact with infants (Chiappini et al., 2013). Tdap should be the vaccine of choice over 
regular tetanus and diphtheria (Td) immunization because it boosts immunity to tetanus 
and pertussis. It is recommended that a booster of Tdap be administered every 10 years, if 
not indicated sooner. 
Due to continued cases of pertussis, the ACIP introduced new guidelines in 2012, 
recommending that women should receive a Tdap vaccination during every pregnancy 
between 27-36 weeks gestation regardless of previous vaccination status. This dose is 
deemed the prenatal or pregnancy vaccination (as cited in Centers for Disease Control, 
2018). It allows the mother to create antibodies which will provide direct immunity to the 
mother and indirect or passive immunity to the infant. During pregnancy, antibodies from 
the mother cross the placental barrier to the infant and can remain present in the infant for 
up to 35-55 days after birth (Abu Raya et al., 2015). This transfer of antibodies is able to 
offer a small degree of protection to the infant until they are able to start receiving 
vaccinations of their own. 
Specific Purpose 
Although steps continue to be made regarding recommendations and current 
vaccination efforts, pertussis rates continue to increase due to decreases in vaccination 
uptake and waning immunity of those previously vaccinated against pertussis. Infants are 




months of age. To best combat this, mothers must receive the Tdap vaccination with 
every pregnancy to transfer a small amount of immunity to the infant. This practice has 
been lacking in acceptance among patients as well as implementation among healthcare 
providers.  
To establish a greater overall immunity to pertussis, it must be determined how to 
best implement and educate the public about these strategies. A lack of public knowledge 
about waning immunity associated with Tdap vaccination was observed as a barrier to 
individuals obtaining a booster vaccination. A study conducted by Suryadevera et al. 
(2014) examined reasons for low immunity coverage. Participants took a survey that 
inquired about factors such as knowledge about pertussis, receipt of booster vaccination, 
and instruction by a health provider to obtain a booster vaccination. Results determined a 
significant lack of knowledge concerning the disease as well as a lack of provider 
recommendation to receive the vaccination. 
This scholarly project will evaluate provider knowledge regarding current 
recommendations concerning maternal prenatal pertussis vaccination before and after a 
teaching in-service. The in-service will highlight the current ACIP Tdap guidelines and 
outline specific instances which require Tdap administration to intrapartum and 
postpartum mothers. The use of a postintervention survey will determine the knowledge 
gained during the in-service as well as the provider’s intention of using it in practice.  
Theoretical Framework 
The theoretical framework for this project uses the Health Belief Model. This 
model was developed in the 1950’s by Godfrey Hochbaum, Irwin Roenstock, and Steven 




screening program for tuberculosis. The Health Belief Model has been utilized to 
describe and promote safety initiatives such as use of seatbelts, oral contraceptives, safe 
sex practices, health screenings, as well as vaccination programs (ReCAPP, 2018).  
The Health Belief Model outlines two beliefs about a particular negative health 
outcome outlined as an individual’s susceptibility and severity. These outcome beliefs are 
balanced against two beliefs about the behavior to prevent the negative outcome 
including perceived benefits and barriers of the individual. These four beliefs drive a 
person to act or not act to prevent the outcome. To begin, an individual must believe 
whether or not they are susceptible to a negative outcome and must also believe whether 
or not they perceive the outcome to be severe. Once a person is convinced of the severity 
of the illness or outcome and his susceptibility, he will take into consideration the 
benefits of the proposed behavior. These benefits may be universally inherent to all 
individuals, may be specific for that individual, or may be a combination. A factor that 
may stand in the way of a person completing the desired task is perceived barriers. Again, 
these may also be universal to all individuals, may be specific for that person, or more 
than likely will be a combination. Barriers can include monetary commitment, time 
constraint, and perceived pain. Other strong barriers can come from level of education 
and cultural or familial beliefs (Resource Center for Adolescent Pregnancy Prevention, 
2020). 
Finally, in order to act, influencing factors must be strong enough to overcome a 
person’s perceived barriers to completing the behavior (Resource Center for Adolescent 
Pregnancy Prevention, 2020). Factors influencing behavior are also called cues to action. 




information received from a health care provider. Other cues include national and local 
health initiatives, and advertisements. 
Once all the available factors have been received by the individual, the perceived 
benefits minus the personal barriers result in the likelihood of a person following through 
with a desired outcome or behavior. While this model can help explain an individual’s 
behavior, it is not meant to be used as a risk assessment, and factors are not considered 
indicators for definite action or lack of action. 
The basis of this project and overall focus will center around the knowledge of 
healthcare professionals regarding maternal Tdap recommendations and their current 
practice discussing recommendations with their patients. Education from health care 
professionals is an important cue to action that can help patients make better informed 
decisions regarding healthcare for themselves or family members. This project also 
worked to determine the current influence from healthcare professionals and whether that 
influence could be stronger as well as help determine if there is a lack of or error in the 




Figure 1:  
Health Belief Model 
 
Project Questions  
1. What is the current knowledge level, attitude, and belief of physicians, 
advanced practice providers, and support staff of obstetric clinics at St. John 
Medical Group in Bartlesville, Oklahoma, regarding national maternal Tdap 
vaccination guidelines? 
2. How will the knowledge, attitude, and beliefs of these healthcare professionals 




Definition of Key Terms 
The key terms and definitions below will provide a basis for the important 
considerations of this project: 
• DTaP- diphtheria, tetanus, and acellular pertussis vaccine, which is given to 
children (CDC, 2019a). 
• Tdap- combined tetanus, diphtheria and acellular pertussis vaccine, which is given 
to adolescents and adults (CDC, 2019a). 
• Booster- a dose of an immunizing substance given to maintain or renew the effect 
of a previous one (Dictionary.com, n.d). 
• Barrier- anything that restrains or obstructs progress (Dictionary.com, n.d). 
• Herd Immunity- the ability of a community to resist epidemic disease (Taber’s, 
1997). 
• Prenatal- occurring, existing, performed, or used before birth (Merriam-Webster 
Dictionary, n.d.).  
• Intrapartum- occurring or provided during the act of birth (Merriam-Webster 
Dictionary, n.d.).  
• Postpartum- occurring in or being the period following childbirth (Merriam-
Webster Dictionary, n.d.). 
• Healthcare Professional- a person associated with either a specialty or a discipline 
and who is qualified and allowed by regulatory bodies to provide a healthcare 




• Primary Care Provider- a health care practitioner who sees people who have 
common medical problems. This person is usually a doctor but may be a 
physician assistant or a nurse practitioner (Medline Plus, 2014).  
• Family Practice Physician- Doctors who have completed a family practice 
residency and are board-certified, or board-eligible, for this specialty. The scope 
of their practice includes children and adults of all ages and may include 
obstetrics and minor surgery (Medline Plus, 2014). 
• Obstetrician/gynecologists (OB/GYN)- Doctors who have completed a residency 
and are board-certified, or board-eligible, in this specialty. They often serve as a 
primary care provider for women, particularly those of childbearing age (Medline 
Plus, 2014). 
• Inpatient- a hospital patient who receives lodging and food as well as treatment 
(Merriam-Webster Dictionary, n.d.).  
• Outpatient- a patient who is not hospitalized overnight but who visits a hospital, 
clinic, or associated facility for diagnosis or treatment (Merriam-Webster 
Dictionary, n.d.).  
Logic Model 
A logic model (Figure 2) for this project was created in order to visually represent 
the process and identify contributing factors to the project. Logic models are able to show 
relationships between ideas and key components within the proposed work. For the 
purpose of this project, key stakeholders were identified as well as proposed activities 
that guide the course of the task. The model is also able to show expected outcomes as 








Vaccines have been an important tool used to eliminate some of the worst disease 
throughout history. As a society, we have forgotten or become indifferent to the serious 
consequences of letting these diseases spread uninhibited. Continued diligence and 
stricter vaccination policies are needed to keep these infections to a minimum or to 
eliminate them completely; unfortunately, it may take a large-scale outbreak of one of 




Despite renewed information and availability of best evidence-based practice 
concerning prevention measures for pertussis transmission, there remains a serious threat 
to young infants and children. According to the CDC (2012), “Pertussis vaccinations 
remain the single most effective strategy for prevention of infection.” Many 
recommendations have been made and adopted regarding timing of booster vaccine 
administration to mothers and family members, but there still is a large gap in vaccination 
rates. These gaps allow for infant exposure and susceptibility to a dangerous yet 
preventable disease. Infants most at risk include those under three months due to severely 
limited or no immunity to pertussis.  
Upon receiving a dose of the Tdap vaccination, the mother starts making 
antibodies that are transferred through the placenta to the fetus, thereby conferring 
passive immunity to the fetus. By vaccinating women during every pregnancy, infants are 
able to start acquiring a small amount of immunity to this disease. Continued education, 
guideline clarification, and research on this phenomenon will better protect future 


















A review of literature concerning strategies for protecting infants from acquiring 
pertussis infections was performed using the electronic databases of PubMed and 
CINAHL. Search criteria consisted of the following: 
• Maternal Immunization 
• Tdap Vaccination 
• Pregnancy  
• Pregnancy Vaccination Rates  
• Pregnancy Vaccination Barriers 
• Infant Pertussis Transmission 
• Infant Pertussis Incidence 
These topics were investigated individually as well as in combination in order to identify 
relevant articles and studies. Additional articles used for the review were found among 
the reference lists of the initial identified sources. All identified search results related to 
maternal Tdap vaccination administration during pregnancy were not used for this 
project. Sources were chosen based on studies or reports generated in the last five years 




publications. Foreign studies were included in the project if they met the above outlined 
criteria for the purpose of adding generalizability to the project. The sources were then 
grouped into subjects:  
• Vaccination Strategies 
• Immunogenicity 
• Vaccine Effectiveness 
• Immunization Safety 
• Barriers to Immunization Administration 
Evidence 
Vaccination Strategies 
The concepts of cocooning, postnatal maternal administration of Tdap, and prenatal 
maternal administration of the Tdap vaccine were identified as strategies against pertussis 
transmission and are outlined below. Further evaluation of each will identify 
effectiveness of the strategy as a stand-alone method or in combination with other 
approaches. Each of these concepts play a role in protecting infants from exposure to 
pertussis and/or providing immunity to infants.  
Cocooning. In 2005, the (ACIP) introduced the concept of “cocooning” which is 
a form of herd immunity (Terranella et al., 2013). The concept of herd immunity 
postulates an individual is protected from a disease if those around them are vaccinated 
against that disease. This decreases the likelihood of the individual coming into contact 
with an infected person. The recommendation stipulated that family members including 
fathers, grandparents, and adolescent siblings should also receive a booster vaccination, 




vaccinated with the booster, allowing the ability to shield or “cocoon” the infant with 
immunity.   
 Postnatal Administration. As a part of the cocooning strategy in 2005, mothers 
received the Tdap vaccine in the immediate postpartum period, referred to as postpartum 
or postnatal vaccination. This practice is still used by some providers today. According to 
Castagnini et al. (2012) maternal vaccination should be included with the family goal of 
immunization not just as a stand-alone measure. Their cross-sectional study discovered 
that only immunizing mothers in the postpartum period made no difference in the 
incidence of pertussis in infants under six months of age. The recommendation from this 
study was that all family members and those frequently encountered by the infant should 
receive a pertussis booster.  
 In an analysis performed of confirmed pertussis cases, it was determined that 
infant risk was reduced by 51% when both the mother and father received the Tdap 
booster; protection is further increased by 16% when older siblings and grandparents 
received the Tdap booster vaccination before delivery (Quinn et al., 2014). This indicates 
that increasing vaccine use in parents and other family members can help decrease infant 
risk for the disease. 
Prenatal Administration. In 2011, the CDC recommended that women who had 
not previously received a booster Tdap immunization be immunized during the third or 
late second trimester of pregnancy. The recommendation was again changed in 2012, and 
women are now encouraged to receive a dose of Tdap between 27-36 weeks gestation of 
every pregnancy, regardless of previous vaccination history. This dose is deemed the 




provide her direct immunity to pertussis. During pregnancy, these antibodies will also be 
able to cross the placental barrier, to the infant, which remain present in the infant for up 
to two months after birth (Abu-Raya et al., 2015). This transfer of antibodies from mother 
to infant is known as indirect or passive immunity. 
  When compared to pre-pregnancy and postpartum Tdap administration, maternal 
intrapartum vaccination has been reported to be the most effective strategy to protect 
infants from contracting pertussis and is “highly protective against infant pertussis, 
especially in the first two months of life” (Baxter et al., 2017). A case-control study of 
pregnancy dosing from 2012-2013 in England revealed an adjusted vaccine effectiveness 
of 93% after comparing incidence of pregnancy Tdap administration to postpartum 
dosing in pertussis confirmed cases to those in the control group (Dabrera et al., 2015). 
Practice Change Guidelines 
In order to identify the most effective maternal/infant Tdap administration 
strategy, a search was performed in regard to current evidence-based practice guidelines 
and recommendations. A report completed by Liang et al. (2018) provides all 
recommendations from the ACIP concerning the above-mentioned strategies regarding 
vaccination of all persons against pertussis, diphtheria, and tetanus. The 
recommendations utilized for this work were selected on the basis of appropriate age 
(childbearing years), disease (pertussis), and condition (pregnancy) of the intended 
population. 
Pregnancy Tdap Guidelines. The ACIP recommends the following Tdap 




• Health care providers should administer a dose of Tdap during every 
pregnancy, regardless of the patient’s prior Tdap vaccination history (Liang et 
al., 2018).  
• Tdap may be administered at any time during pregnancy; however, for full 
benefits it should be given between 27 and 36 weeks’ gestation (Liang et al., 
2018).   
• If a woman did not receive Tdap during the current pregnancy nor has she 
ever received a prior dose of Tdap, then Tdap should be administered in the 
immediate postpartum period (Liang et al., 2018). 
• If a woman did not receive Tdap during her current pregnancy; however, she 
did receive a dose of Tdap previously, she does not require Tdap 
administration in the postpartum period (Liang et al., 2018). 
Recommendation Evaluation. Each vaccination recommendation set forth from 
the ACIP is developed using select criteria to ensure the best and most accurate evidence-
based approach. The criteria used for this is the Grading of Recommendations, 
Assessment, Development, and Evaluation (GRADE) criteria. Elements assessed in this 
evaluation include benefits, harms, quality of evidence, and other socioeconomic 
considerations (National Center for Immunization and Respiratory Diseases, 2019). The 
recommendations were further assessed using the AGREE II tool (Appendix D). The 
AGREE II tool uses specific scored criteria within different domains to rate the strength 
of evidence to which it is applied. It was determined the ACIP recommendations were 
high in quality of evidence as well as strong recommendation strength based on amount 





To understand the differences in protection conferred to infants by varying the 
timing of the Tdap vaccination, one must consider immunogenicity. Immunogenicity is 
the level of protection against an antigen. Serologic pertussis antibody levels are used to 
determine the amount or level of immunogenicity or protection against this disease. 
Infants receive this protection through the transplacental passage from mother to fetus of 
maternal derived antibodies in response to the administration of the Tdap vaccine to the 
mother during pregnancy (Gkentzi et al., 2017). Multiple studies identified in the 
literature review by Gkentzi et al. (2017) measured the immunological effect of prenatal 
maternal Tdap vaccination in regard to timing of the vaccination with pregnancy. In these 
studies, pertussis antibody levels were compared in the mother’s blood as well as infant’s 
cord blood to determine effectiveness and in some cases optimal timing of vaccine 
administration.  
A previous test conducted by Abu Raya et al. (2014) compared antibody serology 
of mother-infant pairs. His team analyzed the maternal levels and infant cord blood levels 
that were immunized at various gestational ages to determine the range for maximum 
antibody referral. Women were grouped by gestational age at which they received the 
Tdap vaccination. The groups were divided into those vaccinated at 27-30 weeks, 31-36 
weeks, and greater than 36 weeks. Infant antibody concentrations were measured at 36 
days, 72 days, and 108 days after birth. It was determined in this study that by 
immunizing mothers between 27-30 weeks gestation, infants had a higher level of 




In the cohort study conducted by Winter et al. (2017), it was determined that 
administration of the Tdap vaccine to mothers between the time of 27-36 weeks gestation 
was more effective than those vaccinated earlier in the second trimester. Although not 
held as a significant finding in this study, it was revealed that infants of mothers 
vaccinated at 27-31 weeks gestation had a lower risk of pertussis than those of mothers 
vaccinated between 32-36 weeks gestation (Winter et al., 2017). A prospective 
observational study agreed that antibody levels of infants of mothers vaccinated earlier 
within the recommended time frame had a higher level of anti-pertussis antibodies than 
those born of women receiving the vaccine later (Eberhardt et al., 2016). 
Healy et al. (2013) found that previously immunized women or those who 
received a Tdap booster before or early in pregnancy would not have the number of 
antibodies sufficient enough to pass to the infant before delivery. Maternal and infant 
cord blood pairs were collected and analyzed for two years on mothers who received the 
Tdap vaccine in different stages of pregnancy including preconception, early during 
pregnancy, and later in pregnancy. It found no difference in antibody levels between 
women vaccinated before pregnancy or early in the pregnancy, and it was determined 
these levels would not be sufficient to protect the infant through two to three months of 
age. This study determined the optimal time for receiving the Tdap vaccine is between 
30-32 weeks (Healy et al., 2013). This protection, however, only benefits the offspring of 
that particular pregnancy. Future pregnancies would require repeated immunization with 
each. 
According to a cohort study, Abu Raya et al. (2015) and associates confirmed that 




waning antibody levels of the mother in the post-partum period. It was observed that 
serum antibody levels were significantly reduced 9-15 months postpartum. These levels 
were, however, found to be higher than their counterparts who were unimmunized during 
pregnancy. The mother is able to retain immunity for herself during this time but does not 
have enough available antibodies to pass to a fetus in subsequent pregnancies. 
Vaccine Effectiveness 
A cohort model study by Teranella et al. (2013) demonstrated the differences in 
effectiveness of prenatal vaccine administration versus cocooning and infant 
immunization with DTaP vaccinations after two months of age. Figures showed a 
decrease in pertussis cases by 20%, hospitalizations by 19%, and deaths by 16% when 
cocooning strategies were compared to infant vaccination beginning at two months of 
age. Further evidence revealed an even more significant reduction in pertussis rates in 
infants whose mothers received the Tdap vaccination in the antepartum period. Antibody 
transfer as a result of maternal pertussis vaccination during pregnancy was shown to have 
33%, 38%, and 49% decreases in pertussis cases, hospitalizations, and deaths 
respectively (Teranella et al., 2013). 
In response to an outbreak of pertussis in England, an observational study was 
completed comparing pertussis cases in varying coverage groups. Researchers examined 
the number of infant pertussis cases, hospitalizations, and deaths as a result of pertussis. 
The study demonstrated an overall vaccine effectiveness of 90% with a 79% decrease in 
infant mortality related to pertussis. Winters (2017), found antibodies received in utero 




at preventing pertussis than cocooning the infant by postpartum maternal Tdap 
administration. 
In a retrospective cohort study conducted by Winter et al. (2017), it was 
determined the antibodies received by the infant in-utero have been shown to be 85% 
more effective at preventing pertussis in infants less than eight weeks old than 
postpartum maternal vaccine administration. In a case control study by Dabrera et al. 
(2015), an adjusted vaccine effectiveness of 93% was found by comparing incidence of 
pregnancy Tdap administration to postpartum dosing. 
In the United States from the years 2010 to 2015, Baxter, et al.  (2017) completed 
a retrospective cohort study of infants born at facilities within the health system Kaiser 
Permanente Northern California (KPNC). The KPNC is a far-reaching organization 
incorporating hospitals, primary care clinics, and pharmacy and laboratory services. 
Participants for the cohort study were infants born greater or equal to 37 weeks gestation 
into the KPNC system to mothers with established care, background, and membership 
within the Kaiser Permanente healthcare system. This strategy allowed for easier 
determination of immunization status as well as availability of medical records 
concerning pregnancy statistics and outcomes, and incidence of infant pertussis cases. Of 
the 17 infants testing positive for pertussis, only one’s mother was vaccinated during 
pregnancy, resulting in a rate ratio of 0.08 with 95% confidence interval. Pregnancy Tdap 
vaccination was calculated to have a 91.4% risk reduction of infant pertussis and a 
calculated vaccine effectiveness of 87.9% from birth to first DTaP dose in first two 




Although there is a high-correlated vaccine effectiveness rate, the pertussis 
vaccination is unable to stop every case of pertussis; however, those infants born of 
mothers receiving the vaccine in the antepartum period have shown to have added health 
benefits for combating the disease (Gentile et al., 2018). In order to determine effects of 
maternal pertussis on disease burden and process, a surveillance study of pertussis cases 
in a hospital setting before and after implementation of a national maternal intrapartum 
Tdap vaccination strategy was conducted by Gentile et al. (2018). Active cases of 
pertussis were identified in the population of patients at a children’s hospital between 
December 1, 2003 and December 31, 2016. The establishment of the intervention was 
initiated in 2012; therefore, cases in 2012 were not included in the results due to the 
possibility of overlapping populations. One postintervention result identified an increase 
in the average age of participants, meaning that those that did contract pertussis on 
average were older at disease occurrence with a decreased incidence in the younger 
population. There was also a decrease in severity of cases, resulting in less 
hospitalizations. One of the most significant results was a complete reduction in mortality 
from pertussis within the study period. Before the intervention, 14 cases of death from 
pertussis occurred within the study period resulting in a 5.9% mortality rate. After the 
intervention, there were no reported mortalities (Gentile et al., 2018).  
Barriers to Immunization Administration 
 Despite recommendations and nationwide efforts to increase pertussis vaccination 
rates among pregnant women actual vaccine coverage remains low (Gkentzi et al., 2017). 
A binary logistic regression method study was conducted by Suryadevera et al. (2014) 




that inquired about factors such as knowledge about pertussis, receipt of booster 
vaccination, and instruction by a health provider to obtain a booster vaccination. It was 
determined there was a significant lack of knowledge concerning the disease as well as a 
lack of provider recommendation to receive the vaccination (Suryadevara et al., 2014). 
 A study conducted by Gauld et al. (2016) identified barriers or reasons for not 
getting the vaccination. Identified barriers included lack of knowledge about the pertussis 
disease and the available vaccine. In some cases, women didn’t remember the topic even 
coming up during prenatal visits, others identified concern about the safety of the vaccine 
while pregnant. Family and anecdotal tradition was another given reason for not 
receiving the vaccination. Those that did receive the Tdap vaccine recalled hearing about 
it from multiple sources including their healthcare providers or settings such as health 
fairs. Other participants noted receiving the vaccine due to the ease of availability from 
their physician’s office or local pharmacy (Gauld et al., 2016).  
A literature review conducted by Gkentzi et al. (2017) concerning vaccination 
uptake strategies identified provider recommendation as being the single most effective 
strategy to increase pertussis acceptance. The review also identified studies originating in 
Mexico, the United Kingdom, and Australia indicating health care provider 
recommendation and education regarding pertussis and the Tdap vaccination as the 
strongest factors affecting maternal receipt of the vaccine. The literature review also 
identified fear of vaccination safety as being the most common reason for refusing the 






To test the safety of administering vaccines to pregnant women a phase I, 
randomized, double-masked, placebo-controlled clinical trial was conducted by Munoz et 
al. (2014). The study found no adverse outcomes for mothers or infants who received the 
prenatal Tdap vaccine. It was noted that all had healthy newborns at and following 
delivery. The most common adverse effect noted with this study was injection site pain 
for the mother. 
Researchers in New Zealand completed a prospective observational study 
regarding the safety of women receiving the Tdap vaccination during pregnancy. The 
study consisted of 739 participants that were followed for four weeks after receiving the 
Tdap vaccination at various times during the intrapartum period. While 31 different 
serious adverse events (SAEs) occurred during this time, none of the SAEs were able to 
be linked or attributed to the mother receiving the pertussis vaccination. They concluded 
that the maternal Tdap vaccination was generally well tolerated by mothers and led to no 
adverse fetal or pregnancy outcomes (Petousis-Harris et al., 2016).  
Lastly, the above-mentioned review of literature by Gkentki et al. (2017) 
consisted of a systematic review of 47 studies evaluating maternal Tdap vaccination 
safety, effectiveness, immunogenicity, and coverage. In regard to safety, a combined 
138,277 pregnancies were identified as receiving the Tdap vaccination among the 47 
studies. The identified studies individually looked at SAEs such as preterm birth, 
stillbirth, low birth weight, duration of hospitalization, obstetric complications, and 




maternal or neonatal outcome related to the mother receiving the Tdap vaccination when 
compared to unvaccinated counterparts (Gkentzi et al., 2017).  
Summary 
Despite renewed information and availability of best evidence-based practice 
concerning prevention measures for pertussis transmission, pertussis remains a serious 
threat to young infants and children. Many recommendations have been made and 
adopted regarding timing of booster vaccine administration to mothers, family members 
and other contacts; still, there is a large gap in vaccination rates. These gaps allow for 
infants to be exposed and susceptible to a dangerous yet preventable disease. Many do 
not realize there is a large gap in protection; others rely on the vaccination of others 
within the community in order to not take steps at vaccination for themselves and their 
family. 
Antibody referral from the mother to the fetus has shown the most significant 
effectiveness limiting the transmission of pertussis to infants. Demonstrated vaccine 
effectiveness of maternal intrapartum vaccination ranges from 85-93% in limiting 
pertussis related illness. Of those contracting the illness, maternal receipt of the vaccine 
in the prenatal period has been effectively shown to reduce the severity of the disease 
process. Combining strategies such as prenatal administration of the Tdap vaccination 
with cocooning has been shown to further increase an infant’s protection. These 
techniques should be used together to allow for maximum effectiveness against this 
disease. Vaccination safety had been proven time and again. The next step is to address 
the most common reason for nonacceptance--lack of provider recommendation. Going 




the importance of these strategies in order to allow them to make their own best-informed 
decisions. Healthcare professionals must be knowledgeable of the best practice guidelines 
and communicate this knowledge with their patients. In light of the information revealed 
with this literature review, assessing the healthcare professionals’ knowledge and practice 
recommendation regarding maternal intrapartum Tdap vaccination administration was the 
focus of this project in order to decrease the pertussis disease burden in our most 


















Immunizing pregnant mothers with Tdap has been shown to be the most effective 
way in preventing acquisition of and/or limiting the severity of pertussis in young infants. 
Despite numerous recommendations and efforts to increase Tdap administration to this 
population, a large number of mothers remain unimmunized during pregnancy (Gkentzi 
et al., 2017). Research has also shown that lack of provider recommendation and 
education regarding Tdap as a main contributing factor of those not receiving the vaccine 
(Suryadevara et al., 2014).  
  Project Design 
This chapter details the design of the completed research project. The intended 
purpose of this project was to (1) evaluated Tdap administration knowledge and practice 
of obstetric health care providers as well as clinical and supportive staff, i.e. nurses, 
medical aides, and others: (2) provided an educational in-service regarding the 
importance of Tdap administration and current recommendations to providers and 
supportive staff, and (3) evaluated knowledge gained and/or intent to change current 
practice by physicians and supportive staff as a result of the educational in-service.  
The study obtained data in the form of a pretest regarding the pre-intervention 




transmission to infants, as well as whether they discuss pertussis with their patients. 
Further data was obtained by the posttest comparing the participants’ perceived increase 
in knowledge regarding pertussis and evaluated the participants’ plan to incorporate that 
knowledge in their future practice.  
Setting 
The Ascension Medical Group St. John Clinic employs multiple physicians and 
offers the only obstetrics coverage in the city of Bartlesville, Oklahoma. The clinic has 
two divisions in obstetrics care: the first is a group of three obstetrician/gynecologists and 
the other is a group of four family practice physicians providing obstetrics care and 
services. Each of the practices employ a number of other healthcare professionals 
including nurse practitioners, nurses, and other support staff. Each office cares for a 
diverse range of patients, both racially/ethnically and socioeconomically.  
Target Population 
The target participants for the study consisted of providers and supportive staff 
working in the St. John Clinics’ family practice and obstetrician/gynecological offices in 
Bartlesville, Oklahoma. Providers include family practice and obstetric/gynecologic 
physicians. Supportive staff included nurses (registered nurses and licensed practical 
nurses) and aides (certified medical aide, certified nurse aide). Projected estimate of the 
number of participants for data collection was 30 to 40 staff members in various 
positions. 
Recruitment and Inclusion/Exclusion Criteria 
 Those participating in the study included healthcare professionals and support 




group. The group gathers multiple times per month during the lunch hour to discuss 
current medical topics and treatments. Permission was obtained from the physicians and 
office managers to present information regarding pertussis and current Tdap 
administration guidelines for pregnant patients. Other participants were welcome to join 
the educational in-service; however, data collected from them was excluded from the data 
pool if their position did not apply to those educating patients on Tdap and pertussis or 
giving the Tdap vaccination. 
Protection of Human Subjects 
An application for approval of investigations involving the use of human subjects 
was completed and submitted to the Pittsburg State University Institution Review Board 
(IRB) for approval to complete the study. According to the Pittsburg State University 
human subjects’ guidelines, this study qualifies for exempt status. Subjects included in 
the study were of age to consent for themselves (over eighteen years of age) and did not 
include any vulnerable or protected individuals or groups such as minors, prisoners, or 
pregnant patients themselves. The study was presented to the human subjects committee 
in order to be reviewed and approved. 
Participation in the study was on a voluntary basis. Verbal disclosure was given 
before beginning the presentation that a participant’s answers would not be revealed to 
their employer or other coworkers in order to prevent retribution. In order to maintain 
confidentiality, pre-tests were previously numbered. Participants were instructed to 
number their post-test with the same number that was on their pre-test. Providing 
corresponding numbers on the tests ensured accuracy and continuity of results while 




and were not and will not be revealed to persons outside of the conductor of the study and 
those completing computations of the data if applicable.  
Ethical Considerations 
Ethical considerations for the study included anonymity of participants and their 
answers obtained from the questionnaires. Demographics on the questionnaires were 
evaluated to determine education levels of the participants in regard to position and years 
of practice. Care was taken to ensure these demographics were not able to identify a 
participant.  
Instruments 
An instrument specific for this study was unable to be found. For this reason, a 
questionnaire instrument was developed in order to assess current knowledge and 
practice for each of the participants regarding patient pertussis and Tdap education and 
administration. Demographics included on the questionnaire assess the position or role of 
the participant, the type of practice in which they worked, and length of time in that 
position. The pre and posttests contain Likert-type, dichotomous, and multiple 
choice/multiple mark questions. The questions evaluated the current knowledge and 
practice of the participant and practice of the office setting in which they work. Three 
questions were select all that apply to assess office practice, barriers to patient Tdap 
education, and barriers to Tdap administration. 
Procedure 
After receiving approval from the IRB for the project, physicians and office 
managers from each of the prospective offices were contacted to gain consent for the 




questionnaires with an educational in-service completed between the tests. The 
participants were given a packet containing both a numbered pretest, a posttest (which the 
participant numbered to match the pre-test), a pregnancy Tdap informational handout 
(appendix C), and a paper copy of the PowerPoint presentation. Participants completed 
the pretest before the educational portion of the presentation. The posttests were removed 
from the packet and completed after the presentation. Both surveys were returned to the 
original packet then collected by the presenter and placed in a locked case. The 
participants were able to keep the other printed information and any notes they had taken.  
Questions on the pretest aimed to determine participants’ knowledge and practice 
regarding pertussis and Tdap vaccination information and guidelines. The first question 
identified the participant’s job status as provider, supportive staff, or other. An additional 
question on the pretest regarding perceived patient barriers or reasons for refusal to 
accept Tdap administration was included to gauge possible future interventions.  
The presentation consisted of a PowerPoint presentation on a screen and 
participants were given a paper form of the presentation in order for participants to 
review information at a later time. Information presented consisted of pertussis definition 
and severity, strategies aimed at combating pertussis, as well as current guidelines and 
recommendations regarding proper maternal Tdap administration and timeline regarding 
pregnancy. A question and answer period followed. Once the question and discussion 
time was completed, the participants were instructed to complete the posttest before 
leaving. The posttest consisted of a number of the same questions from the pretest 
reworded in order to gauge information learned and the participants intention of practice 




Additional information was given in the form of a paper handout from the CDC. 
The handout, titled “You Can Start Protecting Your Infant from Whooping Cough Before 
Birth,” is an information sheet produced by the CDC. This article details the risks and 
harms associated with pertussis, steps pregnant women can take in order to protect their 
infant from whooping cough, and also the safety of the Tdap vaccine. It is endorsed by 
the American Academy of Pediatrics, the American Academy of Family Physicians, 
American College of Obstetricians and Gynecologists, and the American College of 
Nurse-Midwives (CDC, 2019b). This sheet was provided in order to demonstrate the 
information that should be given to and discussed with all mothers regarding pertussis 
and the Tdap vaccine. Evaluation of this information sheet was done using the Patient 
Medical Educational Tool (PMET). This tool evaluates patient education material for 
ease of understanding by patients and those without high health literacy. It rates 26 
individual aspects of the education material on clarity, simplification of verbiage, layout, 
and design. These aspects are scored as disagree, agree, or not applicable. The agree 
responses receive a point, disagree responses receive no point, and not applicable 
responses are not counted in the total possible. The points are calculated then divided by 
the number of points possible which gives a percentage on the strength of the material. 
The CDC’s handout received a score of 93.7% on understandability, and a score of 83% 
for actionability. Points reduced for scoring this material was due to lack of visual aids on 
the handout. Despite the limited visual aids, the material is easy to read and understand 






Evaluation Measures. Evaluation of the data collected determined the provider’s 
and support staff’s current knowledge of the pertussis disease as well as current practice 
prior to receiving the educational presentation. These values were then compared to those 
obtained after the in-service to determine if knowledge levels increased. It also evaluated 
the intention of the participant to improve future practice in regard to discussing Tdap 
vaccination with patients and their families. These measures are discussed further in the 
next chapter. 
 Instrument Linked to Measures. The measurement tool used for this study was 
a pretest and posttest format. These tools were developed specifically for this project. In 
order to test the validity and significance of the tools, they were distributed to health care 
professionals in the field of obstetrics to determine ease of understandability and 
significance of application to the project. To score the tools, a rubric was used on each of 
the questions except the demographics. Items were scored on a 1-4 scale regarding the 
significance to the study. A score of 1 indicates the question is not relevant to the study, 2 
indicates the study is somewhat relevant, 3 indicates quite relevant, while 4 indicates very 
relevant. The average score for validity of the tool was 37/40. Additional comments and 
input from evaluators were considered and implemented on some items to improve 
understandability and ease of use of the tools.   
Methods of Analysis. Excel spreadsheets were utilized in order to complete 
statistical analysis of the data. Statistics gathered evaluated the knowledge of pertussis 
and Tdap in all participants combined. Further evaluation will examine the differences in 




OB/GYN physicians as well as supportive staff to evaluate the population most in need of 
the intervention and possible continued efforts in the future. Likewise, comparing and 
contrasting of individual responses was completed on additional topics, such as current 
practice discussing these topics with patients. Data collected from the survey following 
the educational presentation evaluated the individuals’ change in knowledge regarding 
pertussis and Tdap as well as their intention to implement it in their future practice. 
Visual aids used for demonstration of acquired data included bar graphs and pie charts.  
Plan for Sustainability 
 Sustainability is described by the Institute for Healthcare Improvement as 
“locking in the progress made by an improvement initiative” (Moran et al., 2017). 
Sustainability of the study will rely on continued evaluation of knowledge and 
implementation of educational training regarding current Tdap vaccination strategies in 
the future. As strategies and recommendations regarding Tdap administration during 
pregnancy have changed throughout the years, it will be the responsibility of the 
providers and supportive staff to stay current with recommendations that affect their 
patient population. The Tdap handout provided in this presentation can serve as a guide 
to help healthcare professionals and patients with information regarding Tdap. Current 
guidelines regarding Tdap administration should be intermittently evaluated by a 
specified person within each clinic setting in order to assess for recommendation 
changes.  
 The pregnancy Tdap handout distributed during the presentation is available as a 
free download and is available on the CDC website (CDC, 2019b). Expected incurred 




order to produce the information sheet to distribute to patients. These costs are expected 
to be low relative to the current use of a printing service for the healthcare system. 
Summary 
Lack of maternal Tdap vaccination represents a great potential for severe health 
disparities in infants. In order to address these gaps in coverage, all healthcare 
professionals must be able to educate patients on the importance of Tdap vaccination and 
proper timing of the vaccine during every pregnancy. Adherence to the ACIP Tdap 
administration guidelines has been shown to decrease the incidence as well as severity of 
pertussis in young infants (Gentile et al., 2018). The goal of this project was to increase 
provider awareness of pertussis vaccination administration practices and evaluate the 
adherence to those guidelines. Educating all healthcare professionals including nurses 
and other staff further increases the ability to confer knowledge to pregnant patients and 
their families the dangers of pertussis and the importance of receiving the vaccine. 
Furthermore, infants will receive passive immunity by way of antibodies from their 



















The data collected with the surveys were descriptive in nature. The intended 
purpose of this project and data collection was to (1) evaluate current Tdap 
administration knowledge and practice of obstetric health care providers as well as 
clinical and supportive staff, i.e. nurses, medical aides, and others: (2) provide 
educational in-service regarding the importance of Tdap administration and current 
recommendations to providers and supportive staff, and (3) evaluate knowledge gained 
and/or intent to change current practice by physicians and supportive staff as a result of 
the educational in-service. The long-term goals of this study are to improve maternal 
intrapartum Tdap vaccination acceptance rates, thereby leading to increased rates of 
immunity against pertussis in newborns up to two months of age.  
Results 
An educational in-service was provided to each of the two types of Ascension 
Medical Group St. John clinics offering obstetrics care in Bartlesville, Oklahoma. 
Immediately prior to the presentation, participants were provided with and completed a 
pre-numbered pre-test. Pre-test results that were compiled included information such as 
participant demographics (position, type of clinic, and time at current position), as well as 




information obtained in the survey related to participants’ personal and healthcare facility 
practice regarding Tdap education and vaccine administration. Participants were then 
shown a PowerPoint regarding pertussis as well as current CDC recommendations 
regarding maternal intrapartum Tdap vaccination strategies. Immediately following the 
presentation, a short question and answer period was completed. Participants were then 
given a post-test and instructed to write the number on the pretest number on this survey. 
The post-test included participants’ perceived increase in knowledge regarding pertussis 
and Tdap recommendations. Other information obtained included their intention to 
discuss this information more with their patients and to improve Tdap administration 
rates.  
Demographics 
Pre and posttest surveys were distributed among those present for the in-service in 
each office setting. The presentation was offered one time to each of the OB/GYN and 
family practice settings at Ascension Medical Group St. John Clinic in Bartlesville, 
Oklahoma. Information obtained about the participants consisted of; type of office 
setting, position, and years at position. Demographic data was included only on the 
pretests. This information was used to contrast and compare knowledge regarding Tdap 
vaccine administration knowledge and practice among participants’ positions, office type, 
and number of years of experience. 
Practice Setting. A total number of 23 respondents (N=23) participated in the 
surveys and in-services. Participants were asked to differentiate if they worked in the 




respondents from each type of office consisted of 52% (n=12) from the family practice 
office and 48% (n=11) from the obstetrics/gynecology office (Figure 3). 
Participant Role. Participants were next asked to identify their position or role 
(Figure 4). Possible choices included providers (physician, nurse practitioner, or 
physician’s assistant), nurses (registered nurse or licensed practical nurse), assistive staff 
(certified medical assistant or medical technician), and other office staff (Figure 3). 
Responses included five (22%) providers, eleven (48%) nurses, four (17%) assistive staff 
members, and three (13%) office staff members.  






Participant’s Years of Experience. The largest group of participants, 35% 
(n=8), have been in their current position or role for 6-10 years (Figure 3). The second 
largest group, 20% (n=6), reported greater than 20 years of experience. The remainder of 
respondents reported experience among 0-2 years for 17% (n=4), 3-5 year 13% (n=3), 
and 11-20 years 9% (n=2). 
Roles per Practice Type. Roles were further evaluated according to office or 
practice type (Figure 4). Of the respondent providers, two were obstetrician/gynecologists 
while three were physicians providing family practice care with obstetrical services. The 
largest group represented in the data consisted of seven nurses from the family practice 
office setting. Four nurses were representative of the OB/GYN group. 
Figure 4 








 The background section of the survey was only included on the pretest surveys. 
Information gathered in this section included the current practice aspects of the different 
clinics. Participants were asked if the clinic in which they worked provided patients with 
informational handouts regarding the Tdap vaccination. They were also asked if their 
offices administered the Tdap vaccination within the clinic, as well as the reason if they 
did not administer the vaccine within the clinic. Finally, it asked about patient provided 
reasons for not receiving the vaccination.  
Office Tdap Practices. Of the two types of offices surveyed, OB/GYN and 
family practice, all respondents from both offices reported that each of the clinics offered 
and administered maternal Tdap vaccinations to their intrapartum patients. One provider 
indicated in the survey, as well as in the discussion following the presentation that they 
did not administer the vaccination in the office setting to Medicaid patients due to lack of 
reimbursement for the vaccine by Medicaid. In this particular office, patients with 
Medicaid coverage were instructed to go to the health department to receive the 
vaccination. 
It was reported that both office types did give informational handouts to patients 
regarding pertussis and Tdap vaccination. Upon further discussion, the informational 
handouts provided by both offices were for pertussis and Tdap in general and not specific 
for pertussis and Tdap during pregnancy. Discussion regarding the specific nature of the 
maternal intrapartum Tdap vaccine was discussed among participants. It was considered 
important by participants to obtain more information for patients regarding the role of the 





 The questionnaire portion of the survey included in both the pretest and post-test. 
Question topics remained the same; however, the manner of asking the question was 
changed. Questions presented on the pretest sought to identify individuals’ current 
practice and their perceived knowledge regarding pertussis prevention and Tdap 
vaccination strategies. Posttest questions were worded to determine participants’ 
perceived increase in knowledge regarding the topics as well as their intention to change 
their practice in the future.  
 Familiarity with Current Pregnancy Tdap Recommendations. All participants 
indicated that they were familiar with recommendations for vaccinating against pertussis 
during pregnancy (Figure 5). Of these, 70% (n=16) reported they were strongly aware of 
recommendations while 30% (n=7) reported they were aware. Following the in-service 
participants were asked to answer the statement “I am more familiar with 
recommendations for vaccinating against pertussis during pregnancy.” Again, all 
participants indicated that they were more familiar with Tdap recommendations during 
the post-test, with 95% of participants (n=22) reporting that they “strongly agreed with 





Figure 5  
Familiarity with Pregnancy Tdap Recommendations 
 
Confident of Pertussis/Tdap Knowledge. Participants were next asked about 
their confidence regarding their knowledge of pertussis and the Tdap vaccine when 
discussing those vaccines with their patients/families (Figure 6). Of the participants 
(N=23), 61% (n=14), “strongly agreed” prior to the in-service that they felt confident in 
their knowledge of the pertussis disease as well as maternal Tdap recommendations. Of 
the remaining participants, 26% (n=6) “agreed” while 13% (n=30) “disagreed” that they 
felt confident regarding their knowledge in order to pertussis and Tdap with their patients 
prior to the educational presentation. Following the presentation, all participants either 




vaccination following the presentation. Furthermore, 91% (n=21) of participants reported 
that they “strongly agreed” that they felt an increase in confidence in their knowledge 
regarding Tdap vaccination strategies following the presentation.  
Figure 6  
Confidence in Tdap Knowledge  
 
Tdap Discussed with Patients. The next question sought to determine the 
individual practices of participants (Figure 7). They were asked in the pretest if they 
currently discussed pertussis and the Tdap vaccine with patients. Of those surveyed, 
(n=6) reported they did not discuss Tdap with patients at that time. In the posttest, all 
participants responded that they intend to discuss pertussis and the Tdap vaccine with 





Figure 7  
Tdap Discussed with Patients 
 
 Barriers to Discussing Tdap with Patients. As a follow-up to the previous 
question, participants were asked to identify their perceived barriers to discussing 
pertussis and the Tdap vaccine with their patients (Figure 8). This was a multiple-choice 
question as participants may several barriers affecting their ability to talk with patients. A 
majority of participants (60%) reported no barrier to discussing pertussis and Tdap 
vaccinations with patients. Others did report, however, that time constraint and lack of 
knowledge prevented them from talking with patients. Following the educational 
presentation, an increased number of participants, 78% (n=18), reported that they will 
have no perceived barrier in discussing these subjects with patients in the future. Some 




discussing pertussis and Tdap strategies with patients. Time constraints are an 
increasingly large factor in healthcare. Improved use of time, time management 
strategies, delegation of tasks, and strong informational handouts could be important 
strategies to address this problem. In regard to continued lack of individuals’ knowledge, 
further individualized research into this subject could be beneficial.  
Figure 8  
Barriers to Discussing Tdap with Patients 
 
Tdap Vaccine to Family Members. As a part of the herd immunity strategy of 
cocooning, family members including fathers, adolescent siblings, grandparents, and 
other close contacts are encouraged to receive the Tdap vaccination before the birth of the 
infant. This allows the family member to build immunity before the infant is born in 
order to keep from passing pertussis to the infant in the first few months (Castagnini et al. 




respondents strongly agreed to being aware of the need for family members to receive the 
Tdap vaccination (Figure 9).  
Figure 9 
Aware of the Need for Family Members to Receive Tdap Vaccine 
 
When asked about current practice of recommending to patients that family 
members receive the Tdap vaccination, all participants reported that they do this (Figure 
10). After discussion of the importance family members receiving the vaccine, 95% 
(n=22) of respondents reported they “strongly agree” while the remaining respondent 






Recommend Tdap Vaccine to Family Members 
 
Additional Statistical Analyses 
In addition to the questions posed for the purpose of this study, an extra question 
was included on the pre-test about the most frequently given reasons that patients failed 
to receive the maternal Tdap vaccination. Participants were able to select from a number 
of reasons patients have given for declining the Tdap vaccination (Figure 11). According 
to the surveyed healthcare professionals, financial concern (10 responses) was the most 
common reason for patients to decline the vaccination. Safety concerns and lack of 
patient knowledge regarding pertussis and the vaccine tied (9 responses each) as the next 
most common reasons for patients to decline the vaccination. Five respondents reported 




vaccination. Lastly, one respondent reported religion was another stated barrier for 
patients.  
Figure 11 




This chapter discussed the results of the project to identify healthcare 
professionals’ current knowledge level, attitude, and belief regarding national maternal 
Tdap vaccination guidelines. It also described how these beliefs changed as a result of 
provided education regarding pertussis and vaccination strategies. The study revealed that 
a majority of those participating in the in-service believed they already knew about 
current maternal intrapartum Tdap vaccination strategies. However, following an 
educational in-service, the respondents reported that they learned new information from 

















The purpose of this study was to evaluate the current knowledge level, attitude, 
and belief of physicians, advanced practice providers, and support staff of obstetric 
providing clinics at Ascension Medical Group St. John Clinic in Bartlesville, Oklahoma, 
regarding national maternal Tdap vaccination guidelines. The second aspect of the study 
sought to determine if and/or how the knowledge, attitude, and beliefs of these healthcare 
professionals would change after receiving education regarding Tdap administration 
guidelines. The study provided an educational presentation to inform participants on the 
current maternal intrapartum Tdap vaccination strategies to improve healthcare 
professionals’ knowledge regarding the vaccination strategy. The overall goal of this 
study was to improve healthcare professionals’ awareness of the current guidelines 
regarding maternal intrapartum Tdap vaccination. 
Relationship of Outcomes to Research   
Identified barriers in the literature to maternal intrapartum Tdap vaccination 
included patient lack of knowledge about the pertussis disease and the available vaccine. 
In some cases, women did not remember the topic being mentioned during prenatal visits. 
Those receiving the Tdap vaccine recalled hearing about it from multiple sources 




information is offered by a reliable and trusted source such as a healthcare professional, a 
patient is more inclined to follow guidelines. 
As results of this study indicate, some healthcare professionals were not confident 
in their knowledge regarding pertussis prevention and maternal intrapartum Tdap 
vaccination strategies for this population. They also reported they were not likely to 
discuss this topic with patients. After completion of the in-service, all participants 
surveyed either “agreed” to “strongly agreed” that they would discuss these subjects with 
their patients.  
Statistically, patients have reported receiving the vaccine due to the ease of 
availability from their physician’s office or local pharmacy (Gauld et al., 2016). Patients 
who are offered vaccination in the clinic setting are more likely to be vaccinated than 
those being instructed to go elsewhere (New et al., 2016). One provider in the survey and 
discussion following the presentation noted they did not administer the vaccination in the 
office setting to Medicaid patients due to lack of reimbursement for the vaccine by 
Medicaid. In this particular office, patients with Medicaid coverage were instructed to go 
to the health department to receive the vaccination. Directing a patient to another location 
to receive the vaccination decreases the likelihood of the patient receiving the vaccine. 
Upon further review of reimbursement regarding the intrapartum Tdap vaccine, other 
offices within the same St. John groups reported full reimbursement of the vaccine and 
administration costs from Medicaid when the vaccine is coded under pregnancy. It was 
determined that reimbursement did exist for patients under Medicaid for the Tdap 
vaccination. Since this determination, the provider has started vaccinating every willing 




Evaluation of Theoretical Framework 
The Health Belief Model (Figure 1.1) was the theoretical framework used for 
illustration purposes of this project. The major assumptions of the Health Belief Model 
postulate that a person will take a desired action if they believe the benefits and calls to 
action outweigh the risks and barriers of such action. In the case of maternal intrapartum 
Tdap vaccine administration, information and advice given by healthcare professionals 
has been identified as a large influencing factor on whether or not someone accepts the 
vaccination. By increasing healthcare professionals’ knowledge regarding pertussis and 
interventions to prevent pertussis one can strengthen the likelihood that they will be able 
to pass this knowledge to their patients increasing the call to action.   
According to the results of this study, a majority of healthcare professionals 
surveyed expressed confidence regarding their knowledge about pertussis as well as the 
recommendations regarding maternal intrapartum Tdap administration; however, all 
participants reported that the educational in-service increased their knowledge regarding 
the subject. Likewise, all participants in the study reported the likelihood that they will 
discuss this topic with their patients in the future. This suggests that all who participated 
in the in-service learned some new information that will enable them to educate their 
patients on the importance of pertussis prevention during pregnancy.  
Evaluation of Logic Model 
The logic model (Figure 1.2) created for this study incorporated the intended 
audience or study participants (physicians/providers, nurses, support staff) as well as the 
intervention (pretest, in-service, posttest). Expected immediate effects or results of the 




Tdap vaccination guidelines. According to results of the surveys, all participants 
indicated an increase in knowledge. The next expected effect was practice changes 
regarding recommendations. All participants expressed an intention to discuss pertussis 
and maternal Tdap vaccine administration with patients.  
Other expected results of the project listed in the logic model have yet to be 
determined. These outcomes include increased rates of maternal intrapartum Tdap 
vaccination which, as evidenced by literature, will lead to a decrease in incidence, 
severity, and/or infant death rates in relation to pertussis cases. Further study will be 
required to determine the effect of this study on these outcomes. One proposed evaluation 
of expected results would be to complete a chart review of rates of Tdap administration 
retroactive to the offering of the educational in-service and compare those rates to those 
occurring after the intervention.  
Limitations 
One observed limitation of the study included participant survey size. During the 
time of the in-services, it was noted that one OB/GYN physician as well as one of the 
family practice group’s physicians were out on medical leave. Two nurse practitioners 
were also out of the office on the day of the presentation. These absences further 
decreased the size of the study as those nurses and/or supportive staff were not available 
to attend the in-service.    
This project focused on the obstetrics providers’ offices within a single health 
system, Ascension Medical Group St. John, in one community, Bartlesville, Oklahoma. If 
participants had been included from a number of health systems and a greater number of 




response to healthcare professionals’ knowledge, recommendation, as well as practice 
regarding maternal Tdap administration.  
Finally, limitations introduced by way of the instrument include the ability to 
accurately determine provider knowledge regarding Tdap recommendations. Participants 
were instructed to consider their own knowledge regarding current Tdap 
recommendations before the in-service was given. This perceived knowledge of the 
individual may have been greater than what it actually was. Since the study revealed that 
91% of the participants responded with a “strongly agree” response to a question 
evaluating that participants knowledge increased regarding Tdap administration, it could 
be possible that some participants did not know as much as they initially thought.   
Implications for Future Research 
Effects of the educational in-service on overall Tdap vaccine administration rates 
and thus decreases in rates and/or severity of pertussis cases was unable to be determined 
due to the expedited nature of the study. An extended time period that would allow for 
evaluation of vaccine rates retroactively in comparison to those after the intervention 
would provide a better example of the results of the in-service. This would be completed 
by a comprehensive chart review of patients in the inpatient labor and delivery setting 
regarding the acceptance of the maternal Tdap vaccination. A retroactive review of 
administration rates would have been compared to the vaccination rates after the in-
service was conducted. This comparison would be able to demonstrate an actual 





Based on the limited number of participants provided by the selected setting for 
this study, a larger scale intervention could be the basis for another study. This study 
would be proposed to incorporate multiple settings and/or communities that may identify 
even larger gaps in knowledge regarding pertussis prevention as well as Tdap vaccination 
strategies. Likewise, informing other healthcare professionals, such as inpatient 
obstetrical nurses may serve to improve the overall knowledge of all healthcare 
professionals providing care to this population.  
Participants in this study were asked to identify the reasons patients frequently 
give for declining the maternal intrapartum Tdap vaccination. Future research or 
consideration should go into evaluating these barriers in the current system. Patient 
education from providers should be tailored to address these concerns. It would also be 
helpful to poll patients directly on their concerns regarding the vaccination or barriers to 
receiving the vaccination. These results may prove to be similar or different than those 
previously identified. Regardless of the result, these factors should be addressed with 
patients and information should be identified and shared. The results to this question were 
provided to the office managers and providers in order to further identify needs that may 
be addressed in the future.  
The complete project will be given to and/or discussed with the department 
manager of the hospital’s inpatient obstetrics unit at Jane Phillips Medical Center in 
Bartlesville, Oklahoma. The same educational in-service that was provided for the 
outpatient clinics will be provided for the inpatient nurses. At that time, current pertussis 




procedures regarding maternal Tdap vaccination strategies in the inpatient setting will be 
reviewed to determine if they are in line with national recommendations. 
Implications for Practice 
Healthcare professionals are one of the biggest contributing factors for 
influencing health behaviors in their patient populations. It is important for healthcare 
professionals to be knowledgeable of diseases and other health disparities. It is also 
imperative for them to stay up to date with current guidelines regarding strategies to 
eliminate or limit these health disparities in order to improve the health of their patients.  
It was reported that both office types provide patients with informational handouts 
to patients regarding pertussis and Tdap vaccination. Upon further discussion, the 
informational handouts were for pertussis and Tdap in general and not specifically about 
pertussis and Tdap during pregnancy. Discussion regarding the specific nature of the 
maternal intrapartum Tdap vaccine was discussed among study participants. It was 
considered important by participants to obtain more information for patients regarding 
the role of the Tdap vaccination during pregnancy.  
The handout provided by the CDC (Appendix C) was discussed as a good piece of 
information to provide obstetric patients. As discussed in the handout provided to 
participants, mothers have the unique ability to start protecting their babies from pertussis 
before a child is even born. There is a short time period in which this protection can be 
maximized in order to offer infants the best protection available to them. Discussion of 
this important topic with mothers needs to be well timed and effective in order to rely the 
importance of the situation to mothers. Once an infant is born, it is too late to confer this 





Pertussis continues to be a prevalent threat to children. This threat has been shown 
to be even greater among infants under two months due to them not yet being immunized. 
In the past, herd immunity was used as the sole strategy to offer protection from pertussis 
to infants. More recently, it was discovered that administering a Tdap vaccination to 
mothers during the intrapartum period offers this vulnerable population the greatest 
chance of protection against pertussis. This protection offers infants, at best, the ability to 
avoid contracting pertussis or, at least, decreases the severity and/or death rates for those 
infants who do contract the illness. Historically, lack of instruction by healthcare 
providers was one of the major reasons cited by patients for not receiving the Tdap 
vaccine (Gauld et al, 2016). By keeping healthcare professionals up to date regarding 
pertussis prevention as well as current Tdap vaccination recommendations, they will be 
better prepared and informed about the subject in order to improve and facilitate 
discussion with patients.  
Participants of this study were provided with verbal as well as paper copies of 
information regarding pertussis and Tdap vaccination strategies. It is the intention of this 
survey was to improve healthcare professionals’ knowledge of this disease and 
prevention in order to address this subject more fully with their patients. Improved dialog 
with patients has been shown to increase vaccination rates, leading to a decrease in 
pertussis cases and/or the severity of the illness. It is important that all healthcare 
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1. What is your position or role? 
___Provider (doctor, nurse practitioner, physician’s assistant) 
___Nurse (RN, LPN) 
___Assistive Personnel (CMA, Tech, Aide) 
___Other (office staff, etc.) 
 


















5. Are Tdap (tetanus/diphtheria/pertussis) vaccinations administered in your office? 
___Yes (skip to #7) 
___No (if no, answer #6) 
___Unsure 
 






7. What reasons do patients give for declining the Tdap vaccine? (Select all that apply) 
___Lack of recommendation by physician 




___Unsure of where to get it 
___Fear of pain from shot 











___Strongly Disagree  
 
2. I feel confident in my knowledge of pertussis and the tetanus/diphtheria/pertussis 




___Strongly Disagree  
 




___Strongly Disagree  
___N/A 
 
4. What barriers do you have to informing patients about the need for Tdap? (select all) 
___None, I talk with all my patients and their families 
___Lack of time 
___Lack of knowledge about current pertussis vaccination strategies and guidelines 
___Perceived lack of interest from patients and families 
___Lack of knowledge of waning (decreasing) immunity to pertussis 
___Other (please list): _____________________________________ 
 
5. I am aware of the need for family members of obstetric patients to get Tdap booster 




___Strongly Disagree  
 











Tdap Administration Survey      Number____ 
Post-Test 
Questionnaire: 





___Strongly Disagree  
 
2. I have increased confidence in my knowledge of pertussis and the 




___Strongly Disagree  
 
3. I plan to discuss pertussis (whooping cough) and the Tdap vaccine with patients in the 
future? 
___ Strongly Agree 
___Agree 
___Disagree 
___Strongly Disagree  
 
4. Barriers that continue to exist in regard to informing patients about the need for Tdap 
in the future include: (select all that apply) 
___None, I will talk with all my patients and their families 
___Lack of time 
___Lack of knowledge about current vaccination strategies and guidelines 
___Perceived lack of interest from patients and families 
___Lack of knowledge of waning (decreasing) immunity to pertussis 
___Other (please list):______________________________________ 
 
5. I am more aware of the need for family members of obstetric patients to get Tdap 




___Strongly Disagree  
 
6. I plan to make recommendations to my obstetric patients’ family members to receive 
























Appendix D: AGREE II 
 
 
